Understanding SARS-CoV-2 transmission using experimental challenge

Wendy Barclay

Theme 5 lead







Acknowledgements

Imperial College London

Jie Zhou

Niluka Goonawardane

Maya Moshe

Fiachra Sweeney


Rebecca Frise

Jonathan Brown

Chris Chiu







G2P-UK

Christine Charman

Priya Mande


Kate Lindsell

Department for
Business, Energy
& Industrial Strategy



Sheila Casserly
Olivia Watson
Madelaine Ocampo
Gabrielle Gainsborough

Respiratory virus transmission is complex and heterogeneous




Experimental infections

- Controlled dose and strain of virus and route of infection
- Controlled environment and behaviour
- Naïve healthy young individuals

- Detect differences in virus shedding
- Study very early events after infection


Experimental Human Infection with SARS-CoV-2




Viral load quantified by

Plaque assay – infectious viruses


qPCR – Viral RNA - E gene









18 of 36 challenged healthy naïve volunteers became infected and uniformly shed high viral loads in throat and nose






Virus was detected in mask and air emitted from infected volunteers




Hands and environmental surfaces were contaminated by infected individuals.



Viral load detected from hands (red circles) and environmental surfaces (open circles). Solid black circles mean positive by viral culture

Virus was detected in mask and air, and environment was contaminated when nasal swabs were positive



The correlation between nasal viral load in viral emissions




Nasal disinfectants could temper the spread of SARS-CoV-2




Covering the nose is important


A few volunteers shed most of the virus: who are they?




Virus emission sometimes coordinated with symptoms and nasal viral load




Virus emission can occur before or in absence of symptoms



Why are a minority of people highly infectious?



Some people emit more material than others.... Even if not infected!



There was no difference in internal controls between infected and non-infected volunteers

Internal controls did not increase during infection in infected volunteers

Infected volunteers who emit more virus also exhale more human material

What we have learned about transmission from human challenge study

1. Heterogeneity in transmission

- We detected virus in breath, air on hands and on environmental surfaces in rooms of infected volunteers.
- Despite equal virus dose and timing and route of infection, volunteers showed heterogeneity in quantity and timing of virus emitted.
- Volunteers who emitted most virus in air also emitted most human marker.
- This implies there are host determinants of infectiousness.

2. Timing of transmission

- Virus emission correlated with viral load in the nose.
- Most infected volunteers emitted virus coincident with symptoms.
- A few infected volunteers emitted virus to the air before any symptoms were recorded. Asymptomatic volunteers can emit virus to the air.

What next? Delta....


- Delta VOC has displaced other SARS-CoV-2 variants due to higher transmissibility
- Can we have a model that reflects higher transmissibility?
- Can we explain it mechanistically?



Measuring exhaled infectious virus from experimentally infected hamsters



Hamsters infected with delta VOC emit more infectious virus



Take home messages

- Experimental infections allow us to understand host factors and viral factors that determine SARS-CoV-2 transmission
- A minority of individuals emit the majority of infectious virus
- Some virus variants are emitted more efficiently

 A delta challenge virus is being manufactured for human challenge studies, in vaccinated volunteers



Isolator for Measuring Aerosol and Droplet GENeratioN

Nicola Yaxley and Susan Gould







IMADGENN







- Healthy volunteers are asked to perform various respiratory exercises directed into the flexible film isolator
- Air samplers and settle plates used to sample respiratory aerosols and droplets
- Using respiratory bacteria as a marker for respiratory pathogens
- Counts of airborne Streptococcus salivarius have been shown to be significantly related to the risk of classroom transfer of measles (Reid et al. 1956)

So far...

- IMADGENN has been used to test the efficacy of face coverings
 Work is in progress to...
 - Understand the risk of different respiratory behaviours
 - Determine the size distribution of respiratory aerosol droplets and the bacteria they contain using the May cascade impactor






Face coverings





 Total respiratory/oral bacterial counts after volunteers had performed a sequence of respiratory exercises (deep breath through nose and mouth, coughing, counting, and singing)




- Face coverings are effective in reducing droplet and aerosol dispersal
- The level of effectiveness can be affected by factors such as gender, and if male, the presence of facial hair

Cascade Impactor





- Using the May cascade impactor we aim to determine the size distribution of respiratory aerosols
- Four progressively smaller jets direct aerosolised samples onto coated glass slides
- Samples with a size distribution between 50 1.5 μ show greatest efficiency (overall sample size range >1 μ and ≤ 200 μ)



| Participant | Total respiratory/oral cfu | | | | | | | |
|--------------------------------|----------------------------|---|-----------------|-----------------|------------------------------------|--|--|--|
| Slide 1 Slide 2 >20 μ <20 μ | | | Slide 3 <7 μ | Slide 4 <3 μ | 10/20 cm centre settle plate | | | |
| 1 | ~140 | 2 | 2 | 1 | 320/310 | | | |
| 2 | 0 | 2 | 0 | 0 | - | | | |
| 3 | 0 | 1 | 2 | 1 | - | | | |
| 4 | 2 | 9 | 2 | 0 | 105/55 | | | |
| 5 | 0 | 3 | 2 | 0 | 228/59 | | | |









Distribution of Droplet Dispersal





 Total respiratory/oral bacterial counts after non-mask wearing volunteers had performed a sequence of respiratory exercises (deep breath through nose and mouth, coughing, counting, and singing)





IMADGENN in Liverpool





Participants:


- Early-stage infection (<5 days)
- Community cases

Location:

 Clinical Research Facility, Royal Liverpool University Hospital

Sample Collection:

- Series of respiratory manouevres
- 10 minutes sampling



Sampling





IMADGENN - samples

- Near patient
- Sartorius style filter
- Anderson sampler

Additional sampling:

- Wearable button sampler
- Room/household air sampling using Sartorius MD8 Airport sampler

Gelatin filters

- Dissolved in DMEM
- PCR
- Culture









Participants

- 25 adults recruited July-November 2021
- 21 used all 3 types of sampler including IMADGENN
- 11 male, 10 female
- Median age: 31.5 years
- 1-7 days post symptom onset (median 4)

| COVID-19 vaccinations | Participants |
|-----------------------|--------------|
| 2 | 16 |
| 1 | 3 |
| 0 | 2 |



Preliminary results from 8 participants



- Targets = N gene, Orf 1ab, S gene
- CT values mid-low 30s



Thank you

Nicola Yaxley

Dr Ginny Moore, Patricia Barkoci, Wilhemina D'Costa, Simon Parks, Allan Bennett Biosafety, UKHSA

Susan Gould

Tom Fletcher, Paul Garner, Lance Turtle, Allan Bennett, Jake Dunning

Thanks to all the volunteers!






sites.manchester.ac.uk/covid19-national-project




Aerosol transmission of SARS-CoV-2 by children & adults

Prof Chris O'Callaghan
Professor of Respiratory & Paediatric Medicine
UCL Great Ormond Street Children's Hospital Institute of Child Health, London, UK
c.ocallaghan@ucl.ac.uk



Respiratory viruses enter the body via the nose, mouth or eyes & infect cells




Preventing a respiratory virus from entering the nose, mouth or depositing in the eyes prevents infection

Early in a pandemic, lack of evidence, does not mean it does not occur

Did the interpretation of 'lack of evidence' slow the response to COVID-19 transmission?

Respiratory viruses leave the body via the nose & the mouth as secretions or large & small aerosol particles



The detection of SARS-CoV-2 RNA in the air cannot presume transmission, since only viable virions can cause disease.


No airborne study to date definitively demonstrates SARS-CoV-2 is of an infectious nature, which offers the most robust evidence of transmissibility.


Evidence of Respiratory Syncytial Virus Spread by Aerosol

Time to Revisit Infection Control Strategies?

Hemant Kulkarni¹, Claire Mary Smith², Dani Do Hyang Lee², Robert Anthony Hirst¹, Andrew J. Easton³, and Chris O'Callaghan²

Kulkhani et al, American Journal of Respiratory & Critical Care Medicine; 2016: 194: 308-16






The effects of coronavirus on human nasal ciliated respiratory epithelium

M.A. Chilvers*, M. McKean*, A. Rutman*, B.S. Myint*, M. Silverman*, C. O'Callaghan*

European Respiratory Journal: 2001:18: 965-70



10¹⁰1

10⁹

10⁸

10⁷·

10⁶-

10⁵-


10⁴


10³-

10²

10¹

PFU/ml






- Unvaccinated and vaccinated children
- Aerosol generating procedures in children
- Vaccinated and unvaccinated adults
- Asymptomatic adults








Adult double vaccinated COVID-19 +ve patients Skin & Fomite (Cycle threshold - CT)

| Day of illness | Nasal/throat swab | Skin swab | Disc 1 | Disc 2 | Disc 3 |
|----------------|-------------------|-----------|--------|--------|--------|
| 2 | 29.646 | ND | Х | Х | Х |
| 1 | 17.169 | 33.614 | 19.954 | 22.005 | Х |
| 3 | 21.417 | ND | 28.682 | 32.837 | Х |
| 7 | 29.496 | 35.401 | 35.915 | 34.643 | 37.052 |
| 7 | 18.058 | 37.42 | 23.91 | 27.192 | 31.444 |
| 7 | 33.178 | 35.318 | 35.564 | ND | 40.602 |
| 7 | 25.34 | 35.75 | 31.057 | 32.687 | 31.45 |

Low CT number suggests more virus

If viral RNA is found it does not mean there is infectious virus


Contact from finger to surface




Preliminary evidence that SARS-CoV-2 from those infected remains infectious for at least one hour




Nasal secretion Omin



Nasal secretion 30min



Nasal secretion 60min





1st stage $d_{50} = 7 \mu m$ 2nd stage $d_{50} = 4.7 \, \mu m$ 3rd stage $d_{50} = 3.3 \, \mu m$ 4th stage d₅₀ = 2.1 μm 5th stage $d_{50} = 1.1 \, \mu m$ 6th stage $d_{50} = 0.65 \, \mu m$

Adult double vaccinated COVID-19 +ve patients Aerosol collection (Cycle threshold - CT)


| Day of illness | Nasal/throat swab | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 | Stage 6 | Filter | Funnel |
|----------------|-------------------|---------|---------|---------|---------|---------|---------|--------|--------|
| | | | | | | | | | |
| 2 | 29.646 | ND | ND | ND | ND | ND | ND | ND | ND |
| 1 | 17.169 | ND | ND | ND | ND | ND | ND | ND | ND |
| 3 | 21.417 | ND | ND | ND | ND | ND | ND | ND | ND |
| 7 | 29.496 | ND | ND | ND | ND | ND | ND | ND | ND |
| 7 | 18.058 | ND | ND | 39.562 | ND | 40.667 | ND | ND | ND |
| 7 | 33.178 | ND | ND | ND | ND | ND | ND | ND | ND |
| 7 | 25.34 | ND | ND | ND | ND | ND | ND | ND | 36.027 |

Low CT number suggests more virus


If viral RNA is found it does not mean there is infectious virus

Does a negative result mean there is no infectious virus present?

Addition of impactor samples to ciliated cultures



Preliminary evidence of SARS-CoV-2 infection of human ciliated epithelium



Each impactor stage collects aerosol of a different aerodynamic diameter



Children home visits (Cycle threshold - CT)

| Day of illness | Nasal/throat swab | Skin swab | Mobile | Door handle | Disc 1 | Disc 2 | Disc 3 |
|----------------|-------------------|-----------|--------|-------------|--------|--------|--------|
| 5 | 24.585 | 36.631 | ND | 39.791 | 35.528 | 34.724 | 33.168 |
| 3 | 36.571 | 36.014 | ND | 37.971 | ND | ND | ND |
| 4 | 24.197 | 36.234 | ND | ND | 34.668 | 36.027 | 38.559 |

| Day of illness | Nasal/throat swab | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 | Stage 6 | Filter | Funnel |
|----------------|-------------------|---------|---------|---------|---------|---------|---------|--------|--------|
| 5 | 24.585 | ND | ND | ND | ND | ND | ND | ND | ND |
| 3 | 36.571 | ND | ND | ND | ND | ND | ND | ND | ND |
| 4 | 24.197 | ND | ND | ND | ND | ND | ND | ND | 33.973 |

Improving collection efficiency






2 stage calibration & fillers & viral concentration

Finding human ciliated cultures that replicate SARS-CoV-2 best



Higher throughput analysis of ciliary culture infections



Understanding aerosol generating procedures

UCL Great Ormond Street Institute of Child Health Aerosol transmission team:

- Dan Lee
- Dr Meera Sunther
- Dr Colin Butler
- Dr Elaine Cloutman-Green
- Prof Chris O'Callaghan

SARS-CoV-2 research collaborators UCL/GOSH

- Dr Daniela Cardinale
- Prof Tim McHugh
- Dr Claire Smith
- Dr Rob Hynds
- Francis Yongblah
- Dr Divya Shah

Sars-CoV-2 Research collaborators Imperial

- Dr Jay Zhou
- Prof Wendy Savage
- Dr Ryan Thwaites

Porton Down

- Dr Allan Bennet
- Dr Barry Atkinson
- Dr Ginny Moore

Acknowledgements



GOSH COVID-19 testing team

COVID-19 grant funders

Health & Safety Executive
Great Ormond Street Children's Charity
Great Ormond Street Hospital's BRC
BBSRC

A question for you

If the next pandemic affected children, are we prepared?